Dr. Myatt joined Macomics in 2021 and previously served as Chief Executive Officer at Azeria Therapeutics, where he led the company’s $45mn Series B financing. Prior, he was Partner at venture capital firm Sixth Element Capital, managing a $100mn oncology venture fund. Successful fund exits include transactions with Novartis, Johnson & Johnson Innovation, Sierra Oncology, Boston Pharmaceuticals, Stemline Therapeutics.

Steve began his career at Cancer Research Technology, responsible for identifying new academic drug discovery opportunities in Cambridge UK and was latterly Head of Alliances, Business Development, establishing drug discovery partnerships between industry and academia